Back to search results

Letermovir for CMV Prevention After Transplant

This study is testing if a medication called letermovir can help prevent cytomegalovirus (CMV) in adults who have received a kidney or liver transplant. CMV is a common virus that can cause problems after transplant. You might be able to join if you are an adult (18 years or older) who has had a kidney or liver transplant and have already been exposed to CMV. The study will measure how well letermovir prevents CMV after 84 days. The current status of this study is unclear.

Study design
This interventional study plans to enroll 146 participants. It is not specified if it is randomized or blinded.
What's involved
You would take one letermovir tablet by mouth, once daily, for 84 days.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for efficacy is measured at 84 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07706166

Letermovir for R+ Study

Not Yet Recruiting
PHASE4Ages 18+InterventionalPrevention
University of Wisconsin, Madison
~146 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Letermovir

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of letermovir as a prophylaxis of CMV
Measured over 84 days

Conditions

Kidney Transplant
Liver Transplant

Explore related trials

Cytomegaloviral InfectionKidney TransplantationLiver TransplantationCytomegaloviral Infection

NCT07706166

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin - Madison

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Al-Adra, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Office of Clinical Research Department of Surgery
[email protected]
608-576-0788
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
Adults who received a kidney transplant, liver transplant, or any combination thereof

Exclusion

Known contraindication to letermovir or its excipients
Current participation in another CMV related study
Unwilling or unable to participate in the study protocol

What this trial measures

  • Efficacy of letermovir as a prophylaxis of CMV84 days

    Efficacy will be measured through comparative rates of antiviral failure. Failure will be defined as withdrawal due to intolerance or breakthrough viral replication to a viral load \>1000 IU/mL.